Touch Bionics, Livingston, Scotland, announced that preliminary results indicate the company achieved total revenue of £15 million (about US $21.8 million) in 2015, an 11 percent increase over 2014. The company said its growth was driven by strong results from its European markets, most notably in Germany, and also in France, where the i-limb is now officially approved and funded by the French governmental health authorities.
“We are pleased with our 2015 performance…,” said Ian Stevens, CEO of Touch Bionics. “We anticipate continued growth from sales of…[i-limb quantum and i-digits quantum] in 2016.”
